TAVI NEWS WEEKLY — 16 Nov 2026
1. What changed this week
[MDT] Neuroguard IEP for TCAR (12 Nov): Contego Medical received an FDA PMA for the Neuroguard IEP implant, delivery and flow-reversal system, and an additional 510(k) clearance for its embolic filter, extending use to transcarotid procedures in patients at higher risk from endarterectomy. Medtronic distributes the device exclusively. In the PERFORMANCE III pivotal study (178 participants) there were no strokes at 30 days, and the ITT major complication rate was 0.69%.
Source:
https://www.massdevice.com/medtronic-contego-claim-new-fda-nods-for-neuroguard-carotid-stent/
[Other] GLP-1 RA class labelling (FDA Drug Safety Communication, 9 Nov): FDA requires all GLP-1 RA products to add a Warnings and Precautions entry on a potential increased risk of NAION. In a meta-analysis of 126 RCTs, the rate was 6.4 vs 3.8 cases per 100,000 person-years with comparators.
Source:
2. Papers / congress abstracts to read
[Edwards] EARLY TAVR secondary analysis (JACC: Cardiovascular Interventions): 29.4% of the 901 randomised patients had at least one Class II AVR indication at baseline. These patients had more primary-endpoint events (24.5% vs 14.5%; HR 1.78), and the relative benefit of early TAVR was similar with or without a Class II indication (P interaction 0.96).
Source:
https://www.jacc.org/doi/10.1016/j.jcin.2026.08.016
3. New Devices in Cardiology and Structural Heart
[Other] CGuard Prime TransCarotid Stent System (InspireMD, 12 Nov): FDA approved a PMA supplement for TCAR use with an embolic protection system named in the labelling. In the CGUARDIANS II pivotal trial (50 patients, 11 US sites), acute device success was 100%, with no death, stroke, MI or stent thrombosis at 30 days.
Source:
4. Advances in Cardiology and Structural Heart Tech
[Other] Heartvue.Proton (Heartvue.ai, 13 Nov): FDA 510(k) clearance for machine-learning software that automates cardiac MRI linear dimensions, ventricular volumes/EF and flow quantification, with physician review of every result. The clearance includes a Predetermined Change Control Plan, so the models can be updated within pre-specified bounds without a new 510(k).
Source:
https://www.mpo-mag.com/breaking-news/fda-clears-ai-powered-cardiac-mri-analysis-platform/
5. Cardiology News
Structural Heart News: Nothing new this run.
Coronary Interventions:
[Other] EPIC17-VERONICA (TCT 2026; TCTMD, 13 Nov): 637 ACS patients after PCI with low platelet reactivity at 30–40 days were randomised to continue ticagrelor/prasugrel or de-escalate to clopidogrel. NACE at 11 months was similar (13.2% vs 11.9%; HR 0.88), and the authors call the underpowered result hypothesis-generating.
Source:
Devices:
[Other] OptimPacing (AHA 2026; NEJM; TCTMD, 9 Nov): in 685 patients with AV block and an expected ventricular pacing burden of at least 20%, LBB pacing reduced death, HF hospitalisation or pacing-induced cardiomyopathy vs RV pacing (8.5% vs 19.2%; HR 0.41). The effect came mainly from pacing-induced cardiomyopathy (0 vs 11.7%), and all-cause death was similar. The trial stopped early, which may have exaggerated the benefit.
Source:
https://www.tctmd.com/news/better-outcomes-lbb-vs-rv-pacing-atrioventricular-block
Electrophysiology: Nothing new this run.